INTRODUCTION: Our objective was to evaluate the long-term efficacy of AdVance METHODS: 86 patients underwent male sling surgery at our center between 2010 and 2017. Data were collected in 2022 from electronic medical records, telephone interviews, standardized and validated questionnaires, including the ICIQ-SF, PGI-I, and Pad Test. RESULTS: Among 86 patients, 16 deceased prior 2022, 16 had no efficacy at the one-month post-operative evaluation, and 4 were lost to follow-up. Adverse events occurred in 25 cases. With a median follow-up of 100 months, efficacy at the end of follow up was observed in 41/86 (48%) patients. Among the 50 patients who had initial postoperative efficacy, 32 (64%) maintained efficacy at the end of follow-up. Loss of efficacy in the remaining 18 patients occurred with a median of 36 months. Quality of life was significantly decreased in the non-effective group of patients. A history of radiotherapy, a history of operated urethral stricture, severe preoperative urinary incontinence, and age ≥70 years were significantly associated with the loss of efficacy in univariate analysis. In multivariate analysis, only severe preoperative urinary incontinence remained significantly associated with loss of efficacy. CONCLUSION: With a median follow-up of 100 months, efficacy at the end of follow up was observed in almost half of all patients.